Janet L. Kwiatkowski

9.1k citations

173 papers · 4.1k indexed · 2 hit papers · h-index 35

Genetics top 0.1%
Hematology top 0.2%
Pediatrics, Perinatology and Child Health top 1%
Molecular Biology
Physiology top 5%

Co-authors: Elliott Vichinsky Patricia J. Giardina Ellis J. Neufeld Alexis A. Thompson Nancy F. Olivieri Ellen B. Fung Felicia Trachtenberg Garrett M. Brodeur
Topics: Hemoglobinopathies and Related Disorders (150 papers)Iron Metabolism and Disorders (74 papers)Blood groups and transfusion (31 papers)
Cited by: Genetics Hematology Pediatrics, Perinatology and Child Health
Journals: The Lancet Blood American Journal of Clinical Nutrition
Partner nations: United States United Kingdom Canada

In The Last Decade

Janet L. Kwiatkowski

162 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support

2020 268 citations Stella T. Chou, Mouaz Alsawas et al. Blood Advances profile →
Thalassaemia

2022 141 citations Janet L. Kwiatkowski et al. profile →

Peers

Countries citing papers authored by Janet L. Kwiatkowski

Since Specialization

Citations

This map shows the geographic impact of Janet L. Kwiatkowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet L. Kwiatkowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet L. Kwiatkowski more than expected).

Fields of papers citing papers by Janet L. Kwiatkowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet L. Kwiatkowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet L. Kwiatkowski. The network helps show where Janet L. Kwiatkowski may publish in the future.

Co-authorship network of co-authors of Janet L. Kwiatkowski

This figure shows the co-authorship network connecting the top 25 collaborators of Janet L. Kwiatkowski. A scholar is included among the top collaborators of Janet L. Kwiatkowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet L. Kwiatkowski. Janet L. Kwiatkowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Post-Approval, Real-World Experience with Betibeglogene Autotemcel for Transfusion-Dependent Beta Thalassemia 2025 ·Transplantation and Cellular Therapy ·(unknown),David F. Friedman,Caitlin W. Elgarten,(unknown),Eugene Khandros,(unknown),(unknown),Lisa Wray,Yongping Wang,Alexis A. Thompson,Janet L. Kwiatkowski,Timothy S. Olson	0
2	Betibeglogene Autotemcel (Beti-cel) Gene Addition Therapy Results in Durable Hemoglobin A (HbA) Production with up to 10 Years of Follow-up in Participants with Transfusion-Dependent β-Thalassemia 2025 ·Transplantation and Cellular Therapy ·Timothy S. Olson,Alexis A. Thompson,Janet L. Kwiatkowski,Jennifer Schneiderman,Isabelle Thuret,Andreas E. Kulozik,Evangelia Yannaki,Marina Cavazzana,Suradej Hongeng,Martin G. Sauer,Adrian J. Thrasher,Ashutosh Lal,John E.J. Rasko,(unknown),Tao Ge,(unknown),(unknown),Mark C. Walters,Franco Locatelli	0
3	Real‐world evidence: Long‐term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years 2024 ·American Journal of Hematology ·Janet L. Kwiatkowski,Alexis A. Thompson,Fernando Tricta,(unknown),(unknown),Caroline Fradette,Sherif M. Badawy	0
4	Neonatal Thrombocytopenia as a Presenting Finding in de novo Pyruvate Kinase Deficiency 2023 ·Neonatology ·Brian M. Dulmovits,K. Taylor Wild,John Flibotte,Michele P. Lambert,Janet L. Kwiatkowski,Christopher S. Thom	0
5	Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open‐label FIRST study 2023 ·Pediatric Blood & Cancer ·Mona Hamdy,Amal El‐Beshlawy,(unknown),Julie Kanter,Baba Inusa,Suzan Williams,David Lee,(unknown),Caroline Fradette,Fernando Tricta,Fatma Soliman Elsayed Ebeid,Janet L. Kwiatkowski,Mohsen Saleh Elalfy	4
6	Gene addition for beta thalassemia 2023 ·Annals of the New York Academy of Sciences ·Janet L. Kwiatkowski	1
7	Defining the Impacts of Iron Overload in Children Receiving Hematopoietic Stem Cell Transplantation for Non-Malignant Hematologic Conditions 2023 ·Blood ·(unknown),Sandra Amaral,Jesse Y. Hsu,Timothy S. Olson,Janet L. Kwiatkowski	0
8	Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years 2022 ·Blood Advances ·Mohsen Saleh Elalfy,Mona Hamdy,Amal El‐Beshlawy,Fatma Soliman Elsayed Ebeid,Mohamed Badr,Julie Kanter,Baba Inusa,Amira Adly,Suzan Williams,Yurdanur Kılınç,David D. Lee,Caroline Fradette,(unknown),(unknown),Fernando Tricta,Janet L. Kwiatkowski	16
9	Hemorrhagic Stroke in Children and Adults With Sickle Cell Anemia: The Post-STOP Cohort 2022 ·Stroke ·Christine K. Fox,(unknown),Nancy K. Hills,Janet L. Kwiatkowski,Julie Kanter,John J. Strouse,Jenifer H. Voeks,Heather J. Fullerton,Robert J. Adams,(unknown)	9
10	Safety and Efficacy Outcomes in Pediatric Patients with Transfusion-Dependent β-Thalassemia (TDT) Receiving Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-thalassemia) Gene Therapy in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies 2021 ·Transplantation and Cellular Therapy ·Mark C. Walters,Janet L. Kwiatkowski,John B. Porter,Suradej Hongeng,Evangelia Yannaki,Andreas E. Kulozik,Martin G. Sauer,Adrian J. Thrasher,Isabelle Thuret,Ashutosh Lal,Ruiting Guo,Weijian Liu,Richard A. Colvin,Franco Locatelli,Alexis A. Thompson	1
11	Resolution of Serious Vaso-Occlusive Pain Crises: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy 2021 ·Transplantation and Cellular Therapy ·Mark C. Walters,Alexis A. Thompson,Markus Y. Mapara,Janet L. Kwiatkowski,Lakshmanan Krishnamurti,Banu Aygün,Kimberly A. Kasow,(unknown),Manfred Schmidt,(unknown),Francis J. Pierciey,(unknown),Ren Chen,Sunita Goyal,Julie Kanter,John F. Tisdale	1
12	Efficacy and Safety of Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-thalassemia) Gene Therapy in 60 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed for up to 6 Years Post-Infusion 2021 ·Transplantation and Cellular Therapy ·Suradej Hongeng,Alexis A. Thompson,Janet L. Kwiatkowski,Franco Locatelli,John B. Porter,John E.J. Rasko,Marina Cavazzana,Martin G. Sauer,Adrian J. Thrasher,Isabelle Thuret,Ashutosh Lal,Andreas E. Kulozik,Evangelia Yannaki,Manfred Schmidt,(unknown),Ruiting Guo,Weijian Liu,Richard A. Colvin,Mark C. Walters	1
13	Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study 2021 ·Blood Advances ·Janet L. Kwiatkowski,Mona Hamdy,Amal El‐Beshlawy,Fatma Soliman Elsayed Ebeid,(unknown),Abdulrahman Alshehri,Julie Kanter,Baba Inusa,Amira Adly,Suzan Williams,Yurdanur Kılınç,David Lee,Fernando Tricta,Mohsen Saleh Elalfy	33
14	Restoring Iron Homeostasis in Pts Who Achieved Transfusion Independence after Treatment with Betibeglogene Autotemcel Gene Therapy: Results from up to 7 Years of Follow-up 2021 ·Blood ·Alexis A. Thompson,Franco Locatelli,Evangelia Yannaki,Mark C. Walters,John B. Porter,Suradej Hongeng,Andreas E. Kulozik,Martin G. Sauer,Adrian J. Thrasher,Isabelle Thuret,Ashutosh Lal,Marina Cavazzana,(unknown),Lin Du,Richard A. Colvin,Janet L. Kwiatkowski	2
15	American Society of Hematology 2020 guidelines for sickle cell disease: transfusion supportbreakdown → 2020 ·Blood Advances ·Stella T. Chou,Mouaz Alsawas,Ross M. Fasano,Joshua J. Field,Jeanne E. Hendrickson,Jo Howard,(unknown),Janet L. Kwiatkowski,France Pirenne,Patricia A. Shi,Sean R. Stowell,Swee Lay Thein,Connie M. Westhoff,Trisha E. Wong,Elie A. Akl	268
16	Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia 2020 ·Blood ·Alexis A. Thompson,Janet L. Kwiatkowski,John B. Porter,Suradej Hongeng,Evangelia Yannaki,Andreas E. Kulozik,Martin G. Sauer,Adrian J. Thrasher,Isabelle Thuret,Ashutosh Lal,Ruiting Guo,Weijian Liu,Richard A. Colvin,Mark C. Walters,Franco Locatelli	7
17	Long-Term Efficacy and Safety of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia: Results in Patients with up to 6 Years of Follow-up 2020 ·Blood ·Janet L. Kwiatkowski,Mark C. Walters,Suradej Hongeng,Franco Locatelli,(unknown),Marina Cavazzana,Ying Chen,Richard A. Colvin,Alexis A. Thompson	8
18	Safety of Deferiprone in Individuals with Sickle Cell Disease 2017 ·Blood ·Janet L. Kwiatkowski,Fernando Tricta,(unknown)	2
19	Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency 2017 ·Blood ·Rachael F. Grace,D. Mark Layton,Frédéric Galactéros,Christian Rosé,Wilma Barcellini,D. Holmes Morton,Eduard J. van Beers,Hassan M. Yaish,Yaddanapudi Ravindranath,Kevin H.M. Kuo,Sujit Sheth,Janet L. Kwiatkowski,Bruce A. Silver,Charles Kung,Marvin B. Cohen,Hua Yang,Penelope A. Kosinski,Lei Hua,Ann Barbier,Bertil Glader	2
20	Acute Silent Cerebral Ischemic Events in Children With Sickle Cell Anemia 2012 ·JAMA Neurology ·Charles T. Quinn,Robert C. McKinstry,Michael M. Dowling,William S. Ball,Michael A. Kraut,James F. Casella,Nomazulu Dlamini,Rebecca Ichord,Lori C. Jordan,Fenella J. Kirkham,Michael J. Noetzel,E. Steve Roach,John J. Strouse,Janet L. Kwiatkowski,Deborah Hirtz,Michael R. DeBaun	48

About Janet L. Kwiatkowski

Janet L. Kwiatkowski is a scholar working on Genetics, Hematology and Pediatrics, Perinatology and Child Health, having authored 173 papers that have together received 4.1k indexed citations. Recurring topics across this work include Hemoglobinopathies and Related Disorders (150 papers), Iron Metabolism and Disorders (74 papers) and Blood groups and transfusion (31 papers). The work is most often cited by research in Genetics (3.0k citations), Hematology (2.4k citations) and Pediatrics, Perinatology and Child Health (836 citations). Janet L. Kwiatkowski has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Elliott Vichinsky, Patricia J. Giardina, Ellis J. Neufeld, Alexis A. Thompson, Nancy F. Olivieri, Ellen B. Fung, Felicia Trachtenberg, Garrett M. Brodeur, Kim Smith‐Whitley and Yeşim Aydınok. Their work appears in journals such as The Lancet, Blood and American Journal of Clinical Nutrition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact